Pedram A, Razandi M, Levin E R
Division of Endocrinology, Veterans Affairs Medical Center, Long Beach, Long Beach, California 90822, USA.
J Biol Chem. 1998 Oct 9;273(41):26722-8. doi: 10.1074/jbc.273.41.26722.
Ligand binding to vascular endothelial cell growth factor (VEGF) receptors activates the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK) and c-Jun N-terminal protein kinase (JNK). Possible cross-communication of ERK and JNK effecting endothelial cell (EC) actions of VEGF is poorly understood. Incubation of EC with PD 98059, a specific mitogen-activated protein kinase kinase inhibitor, or transfection with Y185F, a dominant negative ERK2, strongly inhibited VEGF-activated JNK. JNK was also activated by ERK2 expression in the absence of VEGF, inhibited 82% by co-transfection with dominant negative SEK-1, indicating upstream activation of JNK by ERK. VEGF-stimulated JNK activity was also reversed by dominant negative SEK-1. Other EC growth factors exhibited similar cross-activation of JNK through ERK. VEGF stimulated the nuclear incorporation of thymidine, reversed 89% by PD 98059 and 72% by Y185F. Dominant negative SEK-1 or JNK-1 also significantly reduced VEGF-stimulated thymidine incorporation. Expression of wild type Jip-1, which prevents JNK nuclear translocation, inhibited VEGF-induced EC proliferation by 75%. VEGF stimulated both cyclin D1 synthesis and Cdk4 kinase activity, inhibited by PD 98059 and dominant negative JNK-1. Important events for VEGF-induced G1/S progression and cell proliferation are enhanced through a novel ERK to JNK cross-activation and subsequent JNK action.
配体与血管内皮生长因子(VEGF)受体结合会激活丝裂原活化蛋白激酶细胞外信号调节激酶(ERK)和c-Jun氨基末端蛋白激酶(JNK)。关于ERK和JNK之间可能影响VEGF内皮细胞(EC)作用的交叉通讯,目前了解甚少。用特异性丝裂原活化蛋白激酶激酶抑制剂PD 98059孵育EC,或用显性负性ERK2 Y185F转染,可强烈抑制VEGF激活的JNK。在没有VEGF的情况下,ERK2表达也可激活JNK,与显性负性SEK-1共转染可抑制82%,表明ERK可在JNK上游激活。显性负性SEK-1也可逆转VEGF刺激的JNK活性。其他EC生长因子也通过ERK对JNK表现出类似的交叉激活。VEGF刺激胸苷掺入细胞核,PD 98059可逆转89%,Y185F可逆转72%。显性负性SEK-1或JNK-1也显著降低VEGF刺激的胸苷掺入。野生型Jip-1的表达可阻止JNK核转位,抑制VEGF诱导的EC增殖75%。VEGF刺激细胞周期蛋白D1合成和Cdk4激酶活性,均被PD 98059和显性负性JNK-1抑制。通过一种新的ERK到JNK的交叉激活以及随后的JNK作用,增强了VEGF诱导的G1/S期进展和细胞增殖的重要事件。